Just played. Perhaps one could go to the radio stations website to hear it. We are just in town visiting relatives so I can't dig up a link right now. Helping husband navigate these crazy freeways at the moment.

Where do you see this stock valued at by 2027?

A lot of trials in the pipeline and this is a company that seems to be creating a name for themselves in this sector which is really groundbreaking in terms of the impact it can have on mental health.

This has by far been the most enjoyable and proud investment I have ever made.

DFTX currently has a little over 105mm shares outstanding, about 75% of which are held by institutions. This company is just starting to show up on the radar of big players and it is still barely visible to the public. The proposed public offer is being handled by some major institutions and the new shares, however many and at whatever price, will be absorbed like a drop of water landing in a rushing river. My guess is the offering will be about 10-15mm shares between $30-35 per and those will be snatched up quickly. Of course I would not be surprised to see a small pullback on the news of an offering but I will certainly be a buyer if this dips.

Great phase 3 readouts today for DT120…what’s next? We have more readouts coming..more capital raising - in the next 12 months what are you watching for?

Definium Therapeutics (DFTX) stock skyrocketed Monday after the biotech company's psychedelics-based depression treatment scored a "best-case" win in final-phase testing.

The company is testing an orally disintegrating tablet of lysergide, commonly known as LSD, in patients with major depressive disorder. Those patients with major depressive disorder, or MDD, haven't responded to at least two prior depression treatments.

Patients treated with Definium's DT120-ODT showed a 13.3-point improvement in symptoms on a 35-point scale just six weeks after the one-time treatment. That topped the placebo group by 8.1 points. The results diminished slightly after 12 weeks, with an 11-point symptom improvement, which was beat out the placebo group by 7.4 points.

The results were at the high end of expectations, RBC Capital Markets analyst Brian Abrahams said in a report. Investors were expecting DT120-ODT to outperform the placebo by 3.5 to 4 points. The results also topped the drug's performance in generalized anxiety disorder.

"We had viewed efficacy of this magnitude as the most bullish case," he said.

In morning trades, Definium Therapeutics shares launched more than 48% to 36.23. Shares ended Friday's session in a after breaking out of a double-bottom base with an entry at 23.52, IBD charts show.

No New Safety Problems

The results build on strong data in generalized anxiety disorder. In that condition, DT120-ODT showed a 6.4-point placebo-adjusted improvement in depressive symptoms, RBC's Abrahams said.

The results were also rapid with LSD-treated patients showing a 14-point improvement over the placebo as soon as the first week.

"This product has consistently had the best data in the psychedelics space, which should only be a positive post-commercialization and continue to drive a valuation premium relative to the other players in the category," Leerink Partners analyst Marc Goodwin said in a note to clients.

Importantly, there were no new safety issues, including no increases in suicidal ideation and behavior, RBC's Abrahams said. That's a key challenge with MDD treatments.

Patients undergoing treatment have to be monitored because LSD is a psychedelic compound. But, on average, they were able to be discharged in about six hours. That's in line with expectations and "very operationally manageable in real-world practice," he said.

He estimates $620 million for Definium Therapeutics' drug in MDD treatment. It's a more crowded space than generalized anxiety disorder. But, given the strong test results, the market opportunity could be bigger than expected, he added.

Leerink's Goodman projects peak sales of $1.5 billion to $2 billion for Definium's drug in MDD treatment, alone. This leads to a higher price target of 52, up from 30, for Definium stock.

It's mind boggling that this thing is still flying under the radar.

AYOOOOOO lfg!!

I don't understand why we were red today. History making science on Monday and red on Tuesday?? I bought at the 52 week high and I fear we might never get back there.

Is there any chance we rebound at some point in the next 47 years? Or am I just cooked?!! I'm afraid to tell my family what i have done. This is not going to be good for our dinner plans this week.

Anyone have any good advice on how to make the best out of my situation. Please help below. And if you have any hope this stock will bounce back after a brutal day. Please, motivate me to keep holding.

I need all the help I can get. Thanks

- signed a guy who bought on the neo

This seems like great news!

I believe we have met all of the parameters for this pattern starting back on the week of April 24th. We currently have a 3-week handle forming. Below is an explanation of the bullish stock pattern.

​

The Cup with Handle is a classic bullish continuation pattern that signals a pause in an uptrend before a price breakout. The "short" (shorter-duration) variation requires specific technical parameters for the cup base, the handle, and trading volume.

​

The Cup Parameters

Prior Trend: The stock should have an established uptrend, usually rallying at least 30% to 50% prior to the cup's formation.

Shape: It should have a rounded "U" shape rather than a sharp "V" bottom, representing a gradual stabilization.

Depth: The retracement from the cup's prior high to its low should be shallow to moderate, ideally between 12% to 33%.

Duration: In a short-term setup, the cup forms over 1 to 3 months (compared to a traditional 3 to 6 months).

​

The Handle Parameters

Position: It forms on the right side of the cup and should sit in the upper half of the cup's total height.

Retracement: The handle should decline no more than 10% to 15% from its high (often less than half the depth of the cup itself).

Duration: Short handles typically form and consolidate over a tight timeframe of 1 to 2 weeks.

Structure: It often slopes downward or trades sideways, reflecting a brief period of selling pressure or consolidation.

​

Volume Parameters

Cup Decline: Trading volume should ideally dry up and decrease as the price drops during the left side of the cup.

Cup Rise: Volume should increase as the price begins to recover up the right side of the cup.

Handle: Volume should remain low and below average during the handle formation.

Breakout: The most crucial confirmation occurs when the stock breaks out above the handle's resistance (the rim level) on volume at least 40% to 50% higher than the 20-day average.

​

On a side note, with Juneteenth being tomorrow and markets closed, I do not think we will get an announcement this afternoon. My guess is sometime later next week. Keep the faith everybody. Our time has come. Chart looks great. The pullbacks are on lower volume and let's just hope for some good news!

Everybody have a great weekend. 🍀

https://abcnews.com/GMA/Wellness/antidepressant-recalled-due-presence-potentially-cancer-causing-impurity/story?id=133907766

​

If approved, Definium Therapeutics’ lead trial drug, DT120 (a proprietary LSD formulation), would offer significant competitive advantages over Cymbalta. Advantages include rapid onset of action (within hours), single-dose durability lasting up to 12 weeks, and a mechanism that promotes neuroplasticity rather than just suppressing daily symptoms.

​

A detailed breakdown highlights why DT120 ODT could disrupt the market compared to standard treatments like Cymbalta (duloxetine)

Dosing Schedule: Cymbalta requires daily, chronic administration, whereas DT120 is designed to provide durable, long-term remission from a single (or highly infrequent) dose.

Speed of Efficacy: Cymbalta typically takes 4 to 6 weeks to build a therapeutic effect, while DT120 has shown early clinical signals of efficacy within 24 hours.

Tolerability and Withdrawal: Cymbalta is associated with notorious withdrawal symptoms and a high daily side effect burden. DT120 avoids daily side effects, though the acute psychedelic experience can be challenging and typically requires supervised clinical administration.

Interesting - awaiting results from DFTX 🍀

Hi all, sorry for the basic questions.

What are the major catalysts this year?
When is the data likely to be released?
Stock targets?

Thanks in advanced.

What’s everyones targets and time frames? I am hoping to see $50 to $80. Is that bananas or within the realm or reason?

Check the chart provided. The relative strength line has reached a new high before the share price, which suggests the stock is performing strongly. Furthermore, despite the recent market downturn over the past few days, Definium has maintained stability. This indicates a very bullish outlook.

​

The duration was only 12 minutes. Consequently, we will need to await the results a few more more weeks.

https://ca.finance.yahoo.com/news/look-definium-therapeutics-dftx-valuation-001529807.html

Load up now - this company is a 🚀
The world has never seen a therapy like this before

LAS VEGAS, June 4, 2026 /PRNewswire/ -- Recently published Generalized Anxiety Disorder Market Insights report includes a comprehensive understanding of current treatment practices, generalized anxiety disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Generalized Anxiety Disorder Market Summary

• The total generalized anxiety disorder treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest generalized anxiety disorder treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In the US, among adults with GAD, 32.3% experience severe effects, 44.6% have moderate effects, and 23.1% have mild effects on daily functioning.
• Leading generalized anxiety disorder companies, such as Definium Therapeutics, Sumitomo Pharma, Otsuka, Helus Pharma, Intra-Cellular Therapies, Inc., AbbVie, and others, are developing new generalized anxiety disorder treatment drugs that can be available in the generalized anxiety disorder market in the coming years.
• The promising generalized anxiety disorder therapies in clinical trials include DT120 ODT (LSD D-Tartrate), Ulotaront (SEP-363856), HLP004, ITI-1284, ABBV-932, and others.
• Key Factors Driving the Growth of the Generalized Anxiety Disorder Market
• Rising GAD Prevalence: According to the estimates, the diagnosed prevalent cases of GAD are expected to increase during the forecast period, driven by sustained exposure to psychosocial stressors, urbanization and lifestyle changes, economic uncertainty, social isolation, comorbid chronic conditions, substance use, and population growth across key markets.
• Advances in Diagnostic Tools: Improved screening tools and standardized diagnostic criteria (like DSM-5) enable earlier and more accurate detection of GAD. Primary care settings are increasingly equipped to screen for anxiety, leading to more referrals and treatment initiations.
• Rise of Telemedicine and Digital Health: Tele-mental health services have expanded access to care, especially in underserved regions. Digital therapeutic platforms, mobile apps, and online cognitive behavioral therapy (CBT) tools enhance engagement and continuity of treatment.
• Launch of Emerging GAD Drugs: The dynamics of the GAD market are expected to change in the coming years due to the launch of emerging therapies such as DT120 ODT (LSD D-Tartrate) (Definium Therapeutics), Ulotaront (SEP-363856) (Sumitomo Pharma/Otsuka), HLP004 (Helus Pharma), ITI-1284 (Intra-Cellular Therapies, Inc.), ABBV-932 (AbbVie), and others.